Orexo AB (publ) (ORXS.XC)

11.06 -0.56 (-4.82%) At close: 04:23PM BST

Orexo AB (publ)

Rapsgatan 7E
Uppsala
Sweden
46 1 87 80 88 00
https://www.orexo.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 113

Description

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.

Corporate governance

Orexo AB (publ)’s ISS governance QualityScore as of 1 June 2024 is 6. The pillar scores are Audit: 6; Board: 2; Shareholder rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.